Targeted therapy for non-small cell lung cancer

Seminars in Thoracic and Cardiovascular Surgery

Volumn 17, Issue 3, 2005, Pages 199-204

  Toloza, Eric M ^a   D'Amico, Thomas A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biologic therapy; Lung cancer; Targeted therapy

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; PACLITAXEL; PHOSPHOTRANSFERASE; PLACEBO; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; THYMIDINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CONTROL; CANCER GENETICS; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG TARGETING; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEMOPTYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR BIOLOGY; NEUROTOXICITY; NONHUMAN; ONCOGENE RAS; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION;

EID: 27744526775     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2005.08.001     Document Type: Article

References (77)

1. A. Jemal T. Murray E. Ward et al. Cancer Statistics 2005 CA Cancer J Clin 55 2005 10-30
2. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710-1717
3. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatinum-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer N Engl J Med 350 2004 351-360
4. T.L. Winton R. Livingston D. Johnson et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer N Engl J Med 352 2005 2589-2597
5. D. Raben B. Helfrich D.C. Chan et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer Clin Cancer Res 11 2005 795-805
6. C.J. Langer Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC [Review] [55 refs] Int J Radiat Oncol, Biol, Phys 58 2004 991-1002
7. C. Gridelli E. Massarelli P. Maione et al. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly Cancer 101 2004 1733-1744
8. E.M. Toloza J.A. Roth S.G. Swisher Molecular events in bronchogenic carcinoma and their implications for therapy Semin Surg Oncol 18 2000 91-99
9. J.A. Roth S.F. Grammer Gene replacement therapy for non-small cell lung cancer: A review Hematol-Oncol Clin North Am 18 2004 215-229
10. S.E. Shackney C.A. Smith A. Pollice et al. Genetic evolutionary staging of early non-small cell lung cancer: The p53-HER-2/neu-ras sequence Thorac Cardiovasc Surg 118 1999 259-269
11. P. Maione A. Rossi G. Airoma et al. The role of targeted therapy in non-small cell lung cancer Crit Rev Oncol-Hematol 51 2004 29-44
12. D.J. Maslyar T.M. Jahan D.M. Jablons Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer Semin Thorac Cardiovasc Surg 16 2004 40-50
13. S. Korfee T. Gauler R. Hepp et al. New targeted treatments in lung cancer-overview of clinical trial Lung Cancer 45 suppl 2 2004 S199-S208
14. H. Yoshiji S. Kuriyama J. Yoshii et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice Hepatology 39 2004 1517-1524
15. A.A. Adjei An overview of fanasyltransferase inhibitors and their role in lung cancer therapy Lung Cancer 41 2003 S55-S62
16. T. Mitsudomi S.M. Steinberg H.K. Oie et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent Cancer Res 51 1991 4999-5002
17. D.H. Phillips A. Hewer C.N. Martin et al. Correlation of DNA adduct levels in human lung with cigarette smoking Nature 336 1988 790-792
18. D.J. Kwiatkowski D.H. Harpole Jr J. Godleski et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications J Clin Oncol 16 1998 2468-2477
19. M. Liu M.S. Bryant J. Chen et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice Cancer Res 58 1998 4947-4956
20. M.N. Dao D.S. Schrump Growth factor receptors as targets for lung cancer therapy Semin Thorac Cardiovasc Surg 16 2004 3-12
21. R. Govindan Cetuximab in advanced non-small cell lung cancer. [Review] [27 refs] Clin Cancer Res 10 2004 4241s-4244s
22. M. Tiseo M. Loprevite A. Ardizzoni Epidermal growth factor receptor inhibitors: A new prospective in the treatment of lung cancer Curr Med Chem Anti-Cancer Agents 4 2004 139-148
23. F.R. Hirsch G.V. Scagliotti C.J. Langer et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: Perspectives for targeted therapies Lung Cancer 41 2003 S29-S42
24. M. Hidalgo L.L. Siu J. Nemunaitis et al. Phase I and pharmacologic study of OPI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 2001 3267-3279
25. J.A. Kern J.C. Slebos B. Top et al. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas J Clin Invest 93 1994 516-520
26. F.R. Hirsch C.J. Langer The role of HER2/neu expression and trastuzumab in non-small cell lung cancer Semin Oncol 31 2004 75-82
27. T.A. D'Amico M. Massey J.E. Herndon et al. A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers J Thorac Cardiovasc Surg 117 1999 736-743
28. T.A. D'Amico T.A. Aloia M.B. Moore et al. Molecular biologic substaging of stage I lung cancer according to gender and histology Ann Thorac Surg 69 2000 882-886
29. J. Baselga C.L. Arteaga Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2005 2445-2459
30. G. Giaccone The role of gefitinib in lung cancer treatment Clin Cancer Res 10 2004 4233s-4237s
31. M. Ranson Epidermal growth factor receptor tyrosine kinase inhibitors Br J Cancer 90 2004 2250-2255
32. P. Krozely Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors Clin J Oncol Nursing 8 2004 163-168
33. J. Baselga D. Rischin M. Ranson et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 20 2002 4292-4302
34. R.S. Herbst A.M. Maddox M.L. Rothenberg et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial J Clin Oncol 20 2002 3815-3825
35. K. Nakagawa T. Tamura S. Negoro et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gifitinib (Iressa, ZD1839) in Japanese patients with solid malignant tumors Ann Oncol 14 2003 922-930
36. M. Ranson L.A. Hammond D. Ferry et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial J Clin Oncol 20 2002 2240-2250
37. M. Fukuoka S. Yano G. Giaccone et al. A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) J Clin Oncol 21 2003 2237-2246
38. M.G. Kris R.B. Natale R.S. Herbst et al. A phase II trial of ZD 1839 (Iressa) in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) Proc Am Soc Clin Oncol 21 2002 292a
39. D. Cella R.S. Herbst T.J. Lynch et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial J Clin Oncol 23 2005 2946-2954
40. R.B. Natale Epidermal growth factor receptor-targeted therapy with ZD1839: Symptom improvement in non-small-cell lung cancer Int J Radiat Oncol, Biol, Phys 59 2004 39-43
41. G. Giaccone D.H. Johnson C. Manegold et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT-1) Ann Oncol 13 2002 40a
42. D.H. Johnson R. Herbst G. Giaccone et al. ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): Results from a phase III clinical trial (INTACT 2) Ann Oncol 13 2002 468a
43. M. Hidalgo L.L. Siu J. Nemunaitis et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 2001 3267-3279
44. R.S. Erbst Erlotinib (Tarceva): An update on the clinical trial program Semin Oncol 30 2003 34-46
45. F.A. Shepherd J. Rodrigues Pereira T. Ciuleanu et al. Erlotinib in previously treated non-small-cell lung cancer New Engl J Med 353 2005 123-132
46. J.S. Ross D.P. Schenkein R. Pietrusko et al. Targeted therapies for cancer 2004 Am J Clin Pathol 122 2004 598-609
47. W.T. Leslie P.D. Bonomi Novel treatments in non-small cell lung cancer Hematol Oncol Clin North Am 18 2004 245-267
48. D. Hanahan J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353-364
49. D.H. Harpole W.G. Richards J.E. Herndon et al. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer Ann Thorac Surg 61 1996 1470-1476
50. T.A. D'Amico Angiogenesis in non-small cell lung cancer Semin Thorac Cardiovasc Surg 16 2004 13-18
51. G.K. Dy A.A. Adjei Novel targets for lung cancer therapy: Part II J Clin Oncol 20 2002 3016-3028
52. G. Fontanini S. Vignati L. Boldrini et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma Clin Cancer Res 3 1997 861-865
53. D.H. Johnson L. Fehrenbacher W.F. Novotny et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184-2191
54. A.B. Sandler D.H. Johnson R.S. Herbst Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer Clin Cancer Res 10 2004 4258s-4262s
55. F.A. Shepherd S.S. Sridhar Angiogenesis inhibitors under study for the treatment of lung cancer Lung Cancer 41 2003 S63-S72
56. M. Dhanabal R. Ramchandran M.J. Waterman et al. Endostatin induces endothelial cell apoptosis J Biol Chem 274 1999 11721-11726
57. T.L. Moser M.S. Stack I. Asplin et al. Angiostatin binds ATP synthase on the surface of human endothelial cells Proc Natl Acad Sci USA 96 1999 2811-2816
58. E.D. DeMoraes W.E. Fogler D. Grant et al. Recombinant human angiostatin (rhA): A phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics (abstr 10) Proc Am Soc Clin Oncol 20 2001 3a
59. J.P. Thomas J. Schiller F. Lee et al. A phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin (abstr 276) Proc Am Soc Clin Oncol 20 2001 70a
60. M.S. Tsao N. Leu J.R. Chen et al. Differential expression of Met/ hepatocyte growth factor receptor in subtypes of non-small cell lung cancers Lung Cancer 20 1998 1-16
61. P. Zhang W.Y. Gao S. Turner et al. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro Mol Cancer 2 2003 1-5
62. C. Casali A. Stefani G. Rossi et al. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung Ann Thorac Surg 77 2004 247-252
63. B. He L. You K. Uematsu et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells Neoplasia (New York) 6 2004 7-14
64. L. You B. He Z. Xu et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells Oncogene 23 2004 6170-6174
65. A.D. Sanlioglu C. Aydin H. Bozcuk et al. Fundamental principals of tumor necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma Lung Cancer 44 2004 199-211
66. C.E. Denlinger B.K. Rundall D.R. Jones Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: The role of NF-kB Semin Thorac Cardiovasc Surg 16 2004 28-39
67. H.L. Phal Activators and target genes of Rel/NF-kB transcription factors Oncogene 18 1999 6853-6866
68. A.S. Baldwin Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kB J Clin Invest 107 2001 241-246
69. D.R. Jones R.M. Broad L.D. Comeau et al. Inhibition of nuclear factor kB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation J Thorac Cardiovasc Surg 123 2002 310-317
70. S.M. Russo J.E. Tepper A.S. Baldwin Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kB Int J Radiat Oncol 50 2001 183-193
71. P.C. Mack A.M. Davies P.N. Lara et al. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer Lung Cancer 41 2003 S89-S96
72. J. Adams V.J. Palombella P.J. Elliott Proteasome inhibition: A new strategy in cancer treatment Invest New Drugs 18 2000 109-121
73. C. Aghajanian S. Soignet D.S. Dizon et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies Clin Cancer Res 8 2002 2505-2511
74. P.C. Mack A.M. Davies P.N. Lara et al. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer Lung Cancer 41 2003 S89-S96
75. P. Marks R.A. Rifkind V.M. Richon et al. Histone deacetylases and cancer: Causes and therapies Nat Rev Cancer 1 2001 194-202
76. M.W. Mayo C.E. Denlinger R.M. Broad et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kB through the Akt pathway J Biol Chem 278 2003 18980-18989
77. N. Marcoux K. Vuori EGF receptor mediates adhesion-dependent activation of the Rac GTPase: A role for phosphatidylinositol 3-kinase and Vav2 Oncogene 22 2003 6100-6106